NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluate the Safety of Linaclotide in IBS-C Patients in China

CompletedN/A

Sponsor: AstraZeneca

Conditions: Irritable Bowel Syndrome-IBS

Countries: China

This is a Multi-center, single arm, observational study to evaluate the safety of linaclotide in IBS-C patients in China. Enrolls approximately 3,000 Chinese patients from 30 participating sites around China and followed up for half year.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* ≧ 18 years old
* Provision of subject informed consent prior to any study procedures
* Has taken at least one dose of linaclotide
* NOT participating in any interventional study currently or during the last 3 months

Exclusion Criteria:

* If linaclotide is contraindicated according to the product prescribing information
* Being unable to comply with study-specified procedure
* Has ever participated in current study before -

Locations (29)

Baotou, China
Beijing, China
Beijing, China
Binzhou, China
Chengdu, China
Chongqing, China
Guangzhou, China
Guangzhou, China
Guangzhou, China
Jinan, China
Leshan, China
Nanchang, China
Nanjing, China
Nanjing, China
Qingdao, China
Shanghai, China
Shanghai, China
Shanghai, China
Shenyang, China
Shenzhen, China
Shenzhen, China
Suzhou, China
Taiyuan, China
Tianjin, China
Ürümqi, China
Wenzhou, China
Wuhan, China
Xi'an, China
Zhengzhou, China